Schema



Eligibility:	**Randomization:**	**Domain Rank:**
-Age 18 to 39 -Within 12 weeks of diagnosis -Performance Status 0-3 -Any stage of cancer -Favorable prognosis	Stratified by sex, race, ethnicity, and age (emerging adults 18-25-year-old vs young adults 26-39-year-old)	Participant Ranks Domain by personal priority at each time point **Fixed PRO:** PROMIS Global, PROMIS standard AYA 5 domains, Common Items **Choice PRO:** PROMIS Global, 5 ranked AYA domains, Common Items

Accrual Goal = 500

Amendment 2 increases the sample size to 500 with 100 additional BIPOC enrollees

3. Selection

3.1 Selection of Patients

Each of the criteria in the checklist that follows must be met in order for a patient to be considered eligible for this study. Use the checklist to confirm a patient's eligibility. For each patient, this checklist must be photocopied, completed and maintained in the patient's chart.

In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28.

ECOG-ACRIN Patient No. _____

Patient's Initials (L, F, M) _

Physician Signature and Date _____

NOTE: CTEP Policy does not allow for the issuance of waivers to any protocol specified criteria (http://ctep.cancer.gov/protocolDevelopment/policies_deviations.htm). Therefore, all eligibility criteria listed in Section 3 must be met, without exception. The registration of individuals who do not meet all criteria listed in Section 3 can result in the participant being censored from the analysis of the study, and the citation of a major protocol violation during an audit, and require reporting to the IRB of record as non-compliance.

All questions regarding clarification of eligibility criteria must be directed to the Group's Executive Officer (EA.ExecOfficer@ecog-acrin.org) or the Group's Regulatory Officer (EA.RegOfficer@ecog-acrin.org).

NOTE: Institutions may use the eligibility checklist as source documentation if it has been reviewed, signed, and dated prior to registration/randomization by the treating physician.

NOTE: Upon activation of Addendum 5, only patients who self-identify as BIPOC (black, indigenous, Latinx and other people of color) patients will be eligible to participate in this study.

3.2 Eligibility Criteria

_____3.3.1 Patient must be ≥ 18 years and ≤ 39 years of age at registration.

_____3.3.2 Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks (84 days) at registration.

_____ 3.3.3 Patient must not have a recurrence or second primary cancer.

_____ 3.3.4 Patients must not have basal cell skin carcinoma.

_____ 3.3.5 Patient must have received, be currently receiving or planning to receive treatment for cancer, including surgery and/or chemotherapy and/or radiation therapy.

_____ 3.3.6 Patient must have an ECOG performance status 0-3.

_____ 3.3.7 Patient must have a life expectancy >24 months.

Rev. Add2 _____ 3.3.8 Patient must be able to complete questionnaires in English or in Spanish.

_____ 3.3.9 Patient must have internet access through computer, tablet, or smartphone.

_____ 3.3.10 Patient must have an email address.

_____ 3.3.11 Patient must have a mobile phone able with text messaging capabilities.

_____ 3.3.12 Patient must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact).

_____ 3.3.13 Patient must be able to provide informed consent.

Rev. Add1 3.3.14 Participation in clinical trials is not an exclusionary criterion in EAQ202. Patients may be dually enrolled in EAQ202 as well as in therapeutic trials, including those involving checkpoint inhibitors.

NOTE: We understand that some therapeutic trials may also collect PRO data (e.g., the cross-NCTN S1826 study in which ECOG-ACRIN is participating), thus creating a potential for overburdening patients. We will be attentive to informing all patients of this potential overburdening as they consider a voluntary decision to register for EAQ202.We will coordinate with the PRO chair(s) of the therapeutic studies to ensure that the integrity of the PRO analyses be preserved.

_____ _____

Physician Signature Date

OPTIONAL: This signature line is provided for use by institutions wishing to use the eligibility checklist as source documentation.